Caribou Biosciences, Inc. (CRBU)
$0.47-6.00%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $47M
- Beta
- 2.31
- P/E (TTM)
- -0.44
- Short % float
- 14.42%
- Days to cover
- 13.1
- SI change
- -0.5%
- 1W
- -58.77%
- 1M
- -63.57%
- vs SPY 1W
- -58.63%
- vs SPY 1M
- -66.07%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 7
- GROWTH
- 26
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-53.5%
REV YoY-
ROE-89.1%
EPS YoY-
ROA-72.4%
GROSS-130
OP-1091
NET-1030
[VALUATION]
P/E TTM-0.44
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.48
P/FCF-
EV/EBITDA-0.45
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E27.17
ALTMAN Z-
CURR RATIO6.49
ND/EBITDA-
BETA2.31
Company news
FAQ
- What is LOPJLB’s current signal on CRBU?
- LOPJLB’s latest quantitative signal on Caribou Biosciences, Inc. (CRBU) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CRBU in?
- Caribou Biosciences, Inc. (CRBU) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Caribou Biosciences, Inc. (CRBU) do?
- Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti…